IndoVac

Coronavirus. SARS-CoV-2

IndoVac is a COVID-19 vaccine developed by Bio Farma, an Indonesian state-owned enterprise. The vaccine is based on a recombinant protein subunit platform, which uses a part of the virus to stimulate an immune response without causing the disease.

Development

The development of IndoVac began in response to the global COVID-19 pandemic. Bio Farma collaborated with various international and local institutions to expedite the research and development process. The vaccine underwent several phases of clinical trials to ensure its safety and efficacy.

Mechanism of Action

IndoVac works by introducing a harmless piece of the SARS-CoV-2 virus, specifically the spike protein, to the immune system. This protein is recognized by the immune system, which then produces antibodies. If the vaccinated individual is later exposed to the actual virus, their immune system can quickly recognize and combat the virus, preventing illness.

Clinical Trials

IndoVac underwent rigorous clinical trials, including Phase I, II, and III trials. These trials were conducted to assess the vaccine's safety, immunogenicity, and efficacy. The results from these trials indicated that IndoVac is effective in preventing COVID-19 and has a favorable safety profile.

Approval and Distribution

The vaccine received emergency use authorization from the Indonesian Food and Drug Authority (BPOM) and has been included in the national vaccination program. Bio Farma has ramped up production to meet both domestic and international demand.

Storage and Administration

IndoVac is stored at standard refrigeration temperatures, making it easier to distribute compared to some other COVID-19 vaccines that require ultra-cold storage. The vaccine is administered in two doses, given several weeks apart.

Impact

The introduction of IndoVac has significantly contributed to the vaccination efforts in Indonesia, helping to curb the spread of COVID-19 and reduce the severity of the disease in vaccinated individuals.

See Also

• COVID-19 vaccine
• Bio Farma
• SARS-CoV-2
• Indonesian Food and Drug Authority

Related Pages

• COVID-19 pandemic in Indonesia
• Vaccination
• Public health